X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.fiercebiotech.com/biotech/vertex-scores-phase-3-gold-after-next-gen-cystic-fibrosis-treatment-goes-against-trikafta
https://www.fiercepharma.com/pharma/while-vertex-gears-next-generation-cf-treatment-trikafta-remains-formidable
https://www.fiercepharma.com/pharma/nices-trikafta-snub-could-portend-another-pricing-standoff-between-vertex-and-uk
https://www.businesswire.com/news/home/20230426005815/en/Vertex-Announces-U.S.-FDA-Approval-for-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-in-Children-With-Cystic-Fibrosis-Ages-2-Through-5-With-Certain-Mutations
https://www.businesswire.com/news/home/20230426005815/en/Vertex-Announces-U.S.-FDA-Approval-for-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-in-Children-With-Cystic-Fibrosis-Ages-2-Through-5-With-Certain-Mutations
https://www.biospace.com/article/releases/vertex-announces-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-for-public-reimbursement-of-cftr-modulators-extended-to-include-trikafta-and-174-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-/?s=100
http://www.pharmatimes.com/news/symkevikalydeco_cleared_for_use_in_young_cf_patients_1358460
https://www.raps.org/news-and-articles/news-articles/2020/6/ema-recommends-eight-new-medicines-refuses-one
https://www.raps.org/news-and-articles/news-articles/2019/11/fda-approves-5-new-costly-drugs-well-ahead-of-acti
http://www.pharmatimes.com/news/impressive_results_for_trikafta_in_cystic_fibrosis_1315050
https://www.businesswire.com/news/home/20191024005409/en/Vertex-Announces-Agreement-NHS-England-Access-Licensed
http://www.pharmatimes.com/news/trikafta_wins_fda_approval_for_cf_1314112
https://endpts.com/vertex-deal-for-scotland-no-deal-for-england/
https://www.statnews.com/2019/08/28/vertex-patient-deaths-cystic-fibrosis-drug/
https://cysticfibrosisnewstoday.com/2019/08/26/fda-grants-priority-review-vertex-1st-triple-combo-cf/
https://www.businesswire.com/news/home/20190820005233/en/FDA-Accepts-New-Drug-Application-VX-445-Elexacaftor
http://www.pmlive.com/pharma_news/vertex_faces_rejection_of_its_cf_medicines_in_scotland_1297326
https://endpts.com/as-negotiations-with-england-labor-on-scotland-rejects-routine-use-of-vertexs-cystic-fibrosis-drugs/
https://www.fiercepharma.com/pharma/vertex-touts-success-symdeko-despite-ceo-turnover-orkambi-stumble
https://www.prnewswire.com/news-releases/fda-expands-approval-of-treatment-for-cystic-fibrosis-to-include-patients-ages-6-and-older-300872824.html
https://endpts.com/the-top-10-blockbuster-drugs-in-the-late-stage-pipeline-evaluate-adds-6-new-therapies-to-heavy-hitter-list/
http://www.pmlive.com/pharma_news/vertex_makes_choice_for_all-important_cf_triple_therapy_1289543
https://endpts.com/finding-a-winner-in-vx-445-vertex-hustles-cf-combo-to-regulators-on-both-sides-of-atlantic/
https://www.biopharmadive.com/news/epizyme-moves-forward-with-cancer-drug-eyes-2020-launch/555834/
http://www.pmlive.com/pharma_news/vertex_an_extreme_outlier_in_pricing_and_behaviour,_says_nhs_england_1276896
https://www.biospace.com/article/vertex-triple-combo-cystic-fibrosis-therapy-shows-hits-primary-endpoints-in-2-phase-iii-trials/
https://www.ema.europa.eu/documents/product-information/symkevi-epar-product-information_en.pdf
https://www.fiercepharma.com/pharma/abbvie-muscles-into-cystic-fibrosis-but-vertex-ceo-says-its-competitive-edge-has-improved
https://www.biocentury.com/bc-extra/company-news/2018-09-04/vertex-finalizes-orkambi-deal-australia
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/07/news_detail_002994.jsp&mid=WC0b01ac058004d5c1
https://pharmaphorum.com/market-access-2/chmp-vertex-symkevi-alnylam-onpattro/
https://www.fiercepharma.com/pharma/patients-wait-for-years-as-vertex-u-k-officials-argue-over-orkambi-price
http://www.epvantage.com/Universal/View.aspx?type=Story&id=793739&isEPVantage=yes
https://endpts.com/vertexs-rapid-fire-phiii-program-hits-a-roadblock-at-the-fda-will-regulators-force-rival-galapagos-to-slow-down-too/
Market Place
Share 
